A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder
Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, Bae S, Renshaw PF
Published in American Journal of Psychiatry
Methodology
Randomized, double-blind, placebo-controlled trial of creatine 5 g/day added to escitalopram for 8 weeks in women with major depressive disorder.
Key Findings
The creatine augmentation group showed significantly greater improvement in Hamilton Depression Rating Scale scores from week 2 onward and higher remission rates than placebo.
Conclusions
Creatine augmentation accelerates and improves antidepressant response in women with major depression.
Limitations
Small, single-country, women-only sample; short duration; requires replication in mixed populations.
Supplements Studied
The creatine augmentation group showed significantly greater improvement in depression scores and higher remission rates than placebo.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Korean government research grants
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.